Overview

Safety, Tolerability and Efficacy of ISIS-GCCRRx in Type 2 Diabetes

Status:
Completed

Trial end date:
2015-05-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy, safety and tolerability of ISIS-GCCRRx in combination with metformin versus placebo + metformin

Phase:

Phase 2

Details

Lead Sponsor:

Ionis Pharmaceuticals, Inc.

Treatments:

Metformin